Veeva Systems (VEEV) Scheduled to Post Quarterly Earnings on Wednesday

Veeva Systems (NYSE:VEEV) is scheduled to be releasing its earnings data after the market closes on Wednesday, August 28th. Analysts expect Veeva Systems to post earnings of $1.53 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Thursday, May 30th. The technology company reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.10. The business had revenue of $650.35 million during the quarter, compared to analyst estimates of $641.73 million. Veeva Systems had a net margin of 22.34% and a return on equity of 12.74%. On average, analysts expect Veeva Systems to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Veeva Systems Stock Performance

NYSE:VEEV opened at $199.25 on Monday. The stock has a 50-day simple moving average of $186.60 and a 200 day simple moving average of $202.28. Veeva Systems has a one year low of $162.72 and a one year high of $236.90. The company has a market capitalization of $32.21 billion, a price-to-earnings ratio of 58.78, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Morgan Stanley lowered their target price on shares of Veeva Systems from $210.00 to $173.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Robert W. Baird increased their price objective on shares of Veeva Systems from $251.00 to $255.00 and gave the stock an “outperform” rating in a report on Wednesday, May 29th. Royal Bank of Canada restated an “outperform” rating and issued a $250.00 price target on shares of Veeva Systems in a research note on Friday, June 21st. Citigroup decreased their price objective on Veeva Systems from $274.00 to $256.00 and set a “buy” rating for the company in a report on Monday, June 3rd. Finally, Stifel Nicolaus reduced their price target on Veeva Systems from $250.00 to $210.00 and set a “buy” rating for the company in a research report on Friday, May 31st. One analyst has rated the stock with a sell rating, six have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $228.27.

Insider Transactions at Veeva Systems

In related news, SVP Jonathan Faddis sold 2,353 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total transaction of $470,600.00. Following the completion of the transaction, the senior vice president now directly owns 9,035 shares in the company, valued at approximately $1,807,000. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Veeva Systems news, CFO Timothy S. Cabral sold 15,000 shares of the business’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $184.33, for a total value of $2,764,950.00. Following the sale, the chief financial officer now owns 8,391 shares of the company’s stock, valued at approximately $1,546,713.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jonathan Faddis sold 2,353 shares of the stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $200.00, for a total transaction of $470,600.00. Following the completion of the transaction, the senior vice president now directly owns 9,035 shares of the company’s stock, valued at approximately $1,807,000. The disclosure for this sale can be found here. 10.50% of the stock is currently owned by corporate insiders.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.